Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

Amer M Zeidan,James Cavenagh,Maria Teresa Voso,David Taussig,Mar Tormo,Isaac Boss,Wilbert B Copeland,Vanessa E Gray,Alessandro Previtali,Tim O'Connor,Shelonitda Rose,Cl Beach,Lewis R Silverman

doi:10.1182/blood-2019-122896

Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

Amer M Zeidan, James Cavenagh + Show 11 more

Open Access

https://doi.org/10.1182/blood-2019-122896

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 63

Affiliation: Bristol-Myers Squibb (Switzerland), Policlinico Tor Vergata, Royal Marsden NHS Foundation Trust, Hospital Clínico Universitario de Valencia, Mount Sinai Hospital, Yale Cancer Center, Barts Health NHS Trust, St Bartholomew's Hospital

#Acute Myeloid Leukemia Pts #Older Acute Myeloid Leukemia + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

Full Text